IPHA — Innate Pharma SA Share News
0.000.00%
Last trade - 00:00- $172.79m
- $159.33m
- €2.79m
Innate Pharma falls as its COVID-19 pneumonia drug fails
Brief: Innate Pharma To Stop Exploring Avdoralimab in Covid-19
Brief: Innate Pharma Presents Preliminary Data From Tellomak Trial Showing Clinical Response For Lacutamab In Mycosis Fungoides
Brief: Innate Pharma: positive set of first data from TELLOMAK
Brief: Innate Pharma Presents New Data On Next-Generation NK Cell Engager Platform At Focis 2021 Annual Meeting
Brief: Innate Pharma To Present New Lacutamab Data From TELLOMAK Trial
U.S. STOCKS ON THE MOVE-Facebook, DocuSign, The9, Innate Pharma
Brief: Innate Pharma Q1 Revenues Down At EUR 4.5 Mln
Brief: Innate Pharma FY Net Loss Widens To EUR 64 Million
Brief: Innate Pharma Advances Lacutamad Clinical Development Program
Brief: Innate Pharma SA Files For Stock Shelf Of Up To $200 Million
Brief: Innate's First NK Cell Engager Selected By Sanofi As Drug Candidate For Development
Innate Pharma: Dropped cancer treatment sinks shares
Brief: Innate Pharma To Return US And EU Lumoxiti Commercialisation Rights To AstraZeneca
French and Benelux stocks-Factors to watch on Friday
Brief: Innate Pharma To Present Additional Efficacy Data For Monalizumab In Combination With Cetuximab
Brief: Innate Pharma Nine-Months Revenue Down At 33.6 Million Euros
Innate Pharma: Jumps on EMA boost for experimental blood cancer drug
Brief: Innate Pharma Receives EMA PRIME Designation For Lacutamab In Sezary Syndrome